Timothy A. Springer - 20 Jun 2024 Form 4 Insider Report for Tectonic Therapeutic, Inc. (TECX)

Footnote F1

Received in exchange for 5,037,245 shares of common stock of Tectonic Therapeutic, Inc., a Delaware corporation ("Tectonic"), pursuant to an Agreement and Plan of Merger dated as of January 30, 2024 (the "Merger Agreement") by and among AVROBIO, Inc., a Delaware corporation ("AVROBIO"), Tectonic and Alpine Merger Subsidiary, Inc., a direct, wholly owned subsidiary of AVROBIO (the "Merger Sub"). Under the terms of the Merger Agreement, on June 20, 2024, Merger Sub merged with and into Tectonic (the "Merger"), with Tectonic surviving the Merger as a wholly owned subsidiary of AVROBIO. Upon the closing of the Merger, each share of Tectonic common stock was converted into the right to receive 0.534419990 shares of the Issuer's common stock, after giving effect to a reverse stock split of the Issuer's common stock of 1-for-12. Subsequent to the Merger, the name of the Issuer was changed from AVROBIO, Inc. to Tectonic Therapeutic, Inc.

Footnote F2

Received in exchange for 2,902,429 shares of common stock of Tectonic on the same terms and conditions as set forth in footnote (1) herein.

Footnote F3

These shares are held by TAS Partners, LLC ("TAS"). The Reporting Person is the sole managing member of TAS and, as such, has sole voting and dispositive power over the shares held by TAS. The Reporting Person disclaims beneficial ownership of the shares held by TAS except to the extent of his pecuniary interest therein and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

Footnote F4

1/3rd of the shares subject to the option will vest on June 20, 2025, and the balance will vest in equal monthly installments thereafter over the next 24 months, subject in each case to the continuous service of the Reporting Person to the Issuer through the applicable vesting date.